Literature DB >> 23246500

Screening of frailty in elderly patients with disability by the means of Marigliano-Cacciafesta polypathology scale (MCPS) and Canadian Study of Health and Aging (CSHA) scales.

A Martocchia1, P Frugoni, I Indiano, L Tafaro, F Comite, A Amici, M Cacciafesta, V Marigliano, P Falaschi.   

Abstract

Frailty is an age-related condition, characterized by a decreased homeostatic reserve and increased vulnerability to stressful events, with high risk of adverse outcomes. The aim of this study was to compare the evaluation of the frailty by the means of the MCPS and the Rockwood criteria. We enrolled 98 patients (mean age ± standard deviation, m ± SD, 80.7 ± 7.0 years) and 20 controls (82.7 ± 3.4 ys), who attended our outpatient clinic for the evaluation of disability and the renewal of driving license, respectively. The multidisciplinary geriatric assessment (MGA) was performed including the administration of the following scales for frailty: MCPS scale (range 0-245), CSHA-Rules-Based Definition of Frailty (CSHA-RBDF) (range 0-3) and CSHA-Clinical Frailty Scale (CSHA-CFS) (range 0-7). The patients and controls showed MCPS=52.39 ± 11.36 and 4.6 ± 3.28, CSHA-RBDF=2.27 ± 0.62 and 0.10 ± 0.44, CSHA-CFS=6.22 ± 0.75 and 2.95 ± 0.51, respectively (p<0.000001). Frailty scores were higher in female than in male (p=0.065 for CSHA-RDBF and p<0.05 for CSHA-CFS). The MCPS scores were significantly related to both CSHA-RDBF (r=0.753, p<0.001) and CSHA-CFS scores (r=0.793, p<0.001). The frailty scales were significantly related to disability, cognitive impairment and polypathology. In conclusion, the frail patient may be a carrier of multiple chronic pathologies and/or of physical/cognitive decline. The frail patient has to be considered the elective geriatric patient, characterized by a continuous multidimensional care requirement. MCPS is an useful tool for the frailty screening and to set up a tailored program of geriatric rehabilitation, in order to prevent or reduce the development of frailty-related complications.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23246500     DOI: 10.1016/j.archger.2012.11.004

Source DB:  PubMed          Journal:  Arch Gerontol Geriatr        ISSN: 0167-4943            Impact factor:   3.250


  5 in total

1.  Considerations in starting a patient with advanced frailty on dialysis: complex biology meets challenging ethics.

Authors:  Mark Swidler
Journal:  Clin J Am Soc Nephrol       Date:  2013-06-20       Impact factor: 8.237

2.  Psychometric Evaluation of the Making it CLEAR Questionnaire: A Resilience Measure for Older Adults.

Authors:  Lucy Whitehall; Sylwia Górska; Robert Rush; Anusua Singh Roy; Linda Irvine Fitzpatrick; Kirsty Forsyth
Journal:  Innov Aging       Date:  2021-08-13

3.  Rationale and design of the allogeneiC human mesenchymal stem cells (hMSC) in patients with aging fRAilTy via intravenoUS delivery (CRATUS) study: A phase I/II, randomized, blinded and placebo controlled trial to evaluate the safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty.

Authors:  Samuel Golpanian; Darcy L DiFede; Marietsy V Pujol; Maureen H Lowery; Silvina Levis-Dusseau; Bradley J Goldstein; Ivonne H Schulman; Bangon Longsomboon; Ariel Wolf; Aisha Khan; Alan W Heldman; Pascal J Goldschmidt-Clermont; Joshua M Hare
Journal:  Oncotarget       Date:  2016-03-15

4.  Long-term outcomes in elderly patients with ANCA-associated vasculitis.

Authors:  Dominic McGovern; Sam P Williams; Katrina Parsons; Tariq E Farrah; Peter J Gallacher; Eve Miller-Hodges; David C Kluth; Robert W Hunter; Neeraj Dhaun
Journal:  Rheumatology (Oxford)       Date:  2020-05-01       Impact factor: 7.580

5.  The Prescription of Vitamin K Antagonists in a Very Old Population: A Cross-Sectional Study of 8696 Ambulatory Subjects Aged Over 85 Years.

Authors:  Patrick Manckoundia; Clémentine Rosay; Didier Menu; Valentine Nuss; Anca-Maria Mihai; Jérémie Vovelle; Gilles Nuémi; Philippe d'Athis; Alain Putot; Jérémy Barben
Journal:  Int J Environ Res Public Health       Date:  2020-09-14       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.